actions of brain natriuretic peptide in thoracic inferior vena caval constriction. Am. J. Physiol. 265 (Regulatory Integrative Comp. Physiol. 34): R1416-R1422, 1993.-Brain natriuretic peptide (BNP) shares structural and functional similarities to atria1 natriuretic peptide (ANP). Although BNP and ANP interact with the same biologically active guanylate cyclase-coupled receptor, recent reports conflict with regard to the biological actions of exogenous BNP in sodium-retaining and edematous states. We studied the biological actions of BNP in normal dogs (n = 5) and sodium-avid dogs with chronic thoracic inferior vena caval constriction (TIVCC) (n = 6). In normal dogs BNP increased glomerular filtration rate, renal blood flow, and urinary sodium excretion and decreased proximal and distal fractional reabsorption of sodium with activation of urinary guanosine 3',5'-cyclic monophosphate (cGMP). These renal actions occurred in association with marked hypotensive actions and activation of systemic cGMP. In TIVCC, a state characterized by chronic reductions of cardiac output, avid sodium retention, edema, and activation of the renin-angiotensin-aldosterone system (RAAS), the renal actions of BNP were absent in association with marked attenuation of the urinary cGMP response. In contrast, an enhanced hypotensive response with preserved activation of systemic cGMP was observed. In neither normal dogs nor TIVCC dogs did BNP inhibit the RAAS. These studies report that BNP is a potent vasoactive and natriuretic peptide with potent proximal and distal tubular actions in normal dogs. These studies also demonstrate that in TIVCC, a model of low cardiac output and congestive failure that results in marked sodium retention with edema in which there is activation of the RAAS, the renal actions of BNP are attenuated while the vasoactive actions are enhanced. natriuretic peptides; thoracic inferior vena caval constriction; guanosine 3',5'-cyclic monophosphate; renal sodium excretion EXOGENOUS ADMINISTRATION of atria1 natriuretic peptide (ANP) results in a marked natriuresis in normal animals and humans (2, 5). In contrast, a marked renal hyporesponsiveness characterizes sodium-retaining edematous states (16, 22). Such renal hyporesponsiveness to ANP may be associated with a blunted renal cGMP response to ANP, which in part may be mediated by angiotensin II (ANG II), receptor downregulation, and enhanced activity of neutral endopetidase 24.11 (4, 24, 34 (28, 31) . Both peptides mediate their biological actions through a common guanylate cyclase-linked receptor termed ANPR*, with guanosine 3',5'-cyclic monophosphate (cGMP) serving as the second messenger (14). The concept of intracellula r cG ,MP as a second messenger for the biological actions of ANP and BNP is supported by recent studies (10, 12) . Specifically, in cultured cells that express the ANPRA guanylate cyclase coupled receptor, ANP and BNP potently increase intracellular concentrations of cGMP (28), and ANP mediates endothelium-independent relaxation and activation of particulate guanylate cyclase in vascular smooth muscle cells (35). More recently plasma and urinary cGMP have been recognized as important biological markers for the actions of ANP in vivo (16).
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Recent studies have demonstrated that brain natriuretic peptide (BNP) is a peptide hormone, initially identified in the porcine brain, that shares structural and functional homology with ANP (27). BNP circulates in normal humans and animals and is synthesized and secreted by cardiac myocytes (18) . Although BNP possesses greater structural variability among species than ANP, porcine BNP administration to the dog and rat results in quantitatively similar natriuretic and hypotensive actions compared with ANP (8, 21) . Furthermore, studies have demonstrated a high degree of homology between the human, porcine, and canine genomes for BNP (23). Although the clearance rate of BNP is reported to be lower than ANP, studies have demonstrated that BNP and ANP are both degraded and c leared by neutral e lndopeptida se 24.11 and the atria1 natriureti .c peptide clearance receptor, ANPRo (28, 31) . Both peptides mediate their biological actions through a common guanylate cyclase-linked receptor termed ANPR*, with guanosine 3',5'-cyclic monophosphate (cGMP) serving as the second messenger (14) . The concept of intracellula r cG ,MP as a second messenger for the biological actions of ANP and BNP is supported by recent studies (10, 12) . Specifically, in cultured cells that express the ANPRA guanylate cyclase coupled receptor, ANP and BNP potently increase intracellular concentrations of cGMP (28), and ANP mediates endothelium-independent relaxation and activation of particulate guanylate cyclase in vascular smooth muscle cells (35) . More recently plasma and urinary cGMP have been recognized as important biological markers for the actions of ANP in vivo (16) .
While the biological significance of BNP as a circulating hormone continues to be defined, plasma BNP has been reported to be elevated in congestive heart failure (CHF), hypertension, and myocardial infarction (13, 19, 20) . The mechanism of this increase has been attributed to enhanced cardiac synthesis and release as well as decreased clearance (18) . Unlike ANP, the biological actions of BNP in sodium-avid and edematous states remain conflicting. demonstrated that pharmacological concentrations of BNP are more natriuretic and less hypotensive in patients with cardiomyopathy compared with normal subjects, yet these patients did not appear to be sodium retaining and were hypertensive.
These findings contrast with a recent study in sodium-retaining rats with high output cardiac failure secondary to an aortocaval fistula in which attenuated natriuretic and hypotensive responses to BNP were demonstrated (11) . Such attenul ated biological responses are similar to the markedly blunted renal responses to ANP in CHF that have been repeatedly demonstrated (16, 22) .
The chronic thoracic inferior vena caval constriction (TIVCC) is a model of low cardiac output and congestive failure that results in marked sod ium re tention with edema in which there is activa tion of the renin-a ngiotensin-aldosterone system (RAAS), but unlike CHF plasma ANP and BNP are not increased (30). TIVCC is also characterized by markedly attenuated renal responses to ANP (15, 22) .
The current investigation was designed with four objectives. First, we sought to further define the biological actions of BNP in vivo specifically focusing on the glomerular and tubular actions and the renal generation of cGMP in the dog under normal physiological conditions. Second, we sought to determine the renal actions of BNP in a sodium-avid state produced by chronic TIVCC to test the hypothesis that these actions would be attenuated. Third, we also determined the actions of BNP upon the RAAS vasoconstrictor system activated in chronic TIVCC and which may be suppressed in vivo and in vitro by ANP. Last, we sought to define the role of chronic reductions in cardiac output produced by TIVCC on the metabolic clearance of BNP.
METHODS
Experiments were performed in two groups of male mongrel dogs weighing between 15 and 25 kg: group 1 (n = 5, control) and group 2 (n = 6, TIVCC). In the TIVCC group, under pentobarbital anesthesia (30 mg/kg) via a right thoracotomy, the thoracic inferior vena cava was constricted by 50% with an adjustable band eight days before the acute studies, as previously described (30). The dogs received, preoperatively and on the first two days postoperatively, prophylactic antibiotic treatment with clindamycin and penicillin and dihydrostreptomycin (Cornbiotic; Pfizer, New York, NY). Dogs were maintained on a normal sodium diet with standard Chow (Lab Canine Diet 5006, Purina Mills, St. Louis, MO) and with free access to water. In both groups, dogs were fasted on the night before the acute experiment and given an oral dose of lithium (300 mg) and free access to tap water. At the time of the acute experiment, the dogs were anesthetized with pentobarbital sodium (30 mg/kg) with supplemental doses given as needed throughout the experiment. The dogs were intubated and ventilated (Harvard Respirator, Millis, MA) on room air supplemented with oxygen at 4 l/min.
The right external jugular vein was exposed and a flow directed balloon-tipped thermodilution catheter (model 9312lA, 7F, American Edwards Laboratories, Santa Ana, CA) was advanced into the pulmonary artery. The right femoral vein and artery were cannulated with polyethylene catheters for the infusion of inulin, saline, BNP, and for the measurement of mean arterial pressure. A left flank incision was made and the left kidney was exposed. The left ureter was cannulated for timed urine collections and an electromagnetic flow probe was placed on the left renal artery and connected to a flow meter (model FM 5010, Carolina Medical Electronics, King, NC). Renal blood flow, arterial pressure, and atria1 pressures were recorded on a Gould Model 2200 strip recorder (Gould Electronics, Cleveland, OH)
After completion of the surgery, a priming dose of inulin was given and a constant infusion of 1 ml/min was begun to maintain plasma levels at ~40-60 mg/dl. The dogs were then allowed to equilibrate for 60 min, during which time cardiorenal function was monitored to ensure a stable experimental preparation. A saline infusion of 1 ml/min was also begun during the equilibration period. The equilibration period was followed by a 30-min baseline clearance (Cl). This was followed by a 15-min lead-in period during which human BNP-32 (Peninsula Laboratories, Belmont, CA) infusion at 50 ng l kg-l l min-l was begun in both groups followed by two 30-min clearances (C2 and C3). During each experimental clearance measurements included mean arterial pressure (MAP), right atria1 pressure (RAP), pulmonary capillary wedge pressure (PCWP), renal blood flow (RBF), and cardiac output (CO) in triplicate by thermodilution. At the midpoint of each clearance period blood was sampled from the aorta for sodium, lithium, inulin, plasma cGMP, plasma renin activity (PRA), and plasma BNP and ANP. At the end of each clearance period urine was measured for volume as well as concentrations of inulin, sodium, lithium, and cGMP.
Glomerular filtration rate (GFR) was measured by clearance of inulin. Plasma and urinary inulin concentrations were measured by the anthrone method (7) . Concentrations of sodium were measured using ion-selective electrodes (Beckman E2A analyzer). Lithium concentrations in plasma and urine were measured by flame emission spectrophotometry (Instrumentation Laboratory, model 357). Whole kidney proximal and distal tubular reabsorption of sodium was estimated by lithium clearance, which is a reliable method for assessing tubular handling of sodium (29). Proximal fractional reabsorption of sodium (PFR& was calculated by the formula PFRN, (%) = [ 1 -(Li clearance/inulin clearance)] x 100. Distal fractional reabsorption of sodium (DFR& was calculated by the formula DFRN, (%) = [ (Li clearance -Na clearance)/(Li clearance)] x 100.
Blood for hormone analysis was collected into EDTA tubes, immediately placed on ice, and centrifuged at 2,500 revolutions/ min at 4°C. Plasma was separated and stored at -2OOC until the assay. Urine for cGMP determination was heated to >9O"C before storage. PRA was determined by radioimmunoassay (RIA) using the method of Haber et al. (9) . Plasma and urine cGMP were determined by a specific RIA as previously described (26) . Renal cGMP generation (RcGMP) was calculated by the formula RcGMP = [(urinary cGMP x urine flow) -(plasma cGMP x GFR)].
Plasma ANP levels were determined by a specific RIA as previously described (3) . Plasma BNP levels were also determined by a specific RIA. One milliliter of plasma was preacidified and extracted on C-8 Bond Elut cartridges and eluted with 1% trifluoracetic acid and 95% methanol. Concentrated eluates were then assayed using a BNP RIA kit (Peninsula Laboratories). Samples or standards were incubated for 24 h at 4°C with 100 ~1 polyclonal antibody raised against BNP. One hundred microliters of lz51-labeled BNP was then added and incubated for another 24 h at 4°C. Free and bound fractions were then separated by adding a second antibody. Samples were centrifuged, supernatant was discarded, and the pellets were counted. Minimum detectable concentration for the assay was 0.5 pg/ tube. Recovery was 75 t 11%, interassay and intra-assay variability were 12 and lo%, respectively. The crossreactivity of the BNP assay to other structurally related peptides was determined by the addition of synthetic ANP-28 (Peninsula Laboratories) in concentrations ranging from 0.5 to 500 pg/tube. There was no detectable immunoreactivity to ANP demonstrating a crossreactivity of ~1%. In addition, synthetic BNP-32 (Peninsula Laboratories) was added to the ANP assay in concentrations ranging from 0.5 to 500 pg/tube with no detectable immunoreactivity, demonstrating a crossreactivity of <l%. Total metabolic clearance rate of BNP (TMCR) was calculated by the formula TMCR = [(infusion rate BNP x weight) / (BNP infused -BNP baseline)] x 1,000.
Data from each clearance period were averaged and expressed as means t SE. Within each group, the mean changes from baseline were assessed by paired Student's t test, and repeated measures were analyzed using analysis of variance followed by Fisher's least significant difference test when appropriate. Comparisons between groups were analyzed by unpaired Student's t tests. Significance was achieved when the P value was ~0.05. urine flow, urinary sodium excretion, and fractional excretion of sodium. Both proximal and distal fractional reabsorption of sodium and renal vascular resistance decreased, In group 2 baseline urinary sodium excretion and fractional excretion of sodium were decreased and proximal and distal tubular reabsorption were increased compared with group 1. BNP decreased distal fractional reabsorption of sodium and renal blood flow. Proximal fractional reabsorption of sodium increased, while glomerular filtration rate, renal vascular resistance, urine flow, urinary sodium excretion, and fractional excretion of sodium did not change. Table 3 reports the hormonal responses to BNP in group 1 and group 2. Plasma renin activity was increased in group 2 and was not changed by BNP administration in either group. In both groups BNP increased plasma, urinary, and renal cGMP generation. There was a tendency for plasma ANP to increase during BNP infusion in both groups, but this was significant only in group 1.
RESULTS
TMCRs for BNP were not different between groups (group 1 TMCR = 13,121 t 2,495 ml/min; group 2 TMCR = 11,053 t 1,303 ml/min; P value NS).
Systemic vascular resistance increased while heart rate did not change. In group 2 baseline cardiac output was decreased and systemic vascular resistance was increased compared with group 1. BNP decreased mean arterial pressure, cardiac output, right atria1 pressure, and pulmonary capillary wedge pressure. Systemic vascular resistance and heart rate did not change. Table 2 reports the renal hemodynamic and excretory responses to BNP in group 1 andgroup 2. In group 1 BNP increased glomerular filtration rate, renal blood flow, Figure 1 illustrates the mean absolute changes from baseline in cardiovascular hemodynamics and plasma cGMP during BNP administration in both groups. There was a greater decrease in mean arterial pressure in the TIVCC group. In contrast, there was a greater decrease in cardiac output in the control group. Systemic vascular resistance increased only in the control group, while the increases in plasma cGMP did not differ between the two groups. Figure 2 illustrates the mean absolute changes from baseline in renal hemodynamic and excretory function and urinary cGMP during BNP administration in both groups. There were greater increases in glomerular filtration rate, renal blood flow, and fractional excretion of sodium in the control group. The increase in urinary parameters is consistent with a decrease in afferent arteriolar tone, which results in an increase in glomerular hydrostatic pressure. BNP also markedly augmented sodium excretions, which were mediated by a decrease in distal tubular reabsorption of sodium consistent with previous reports (21). All of these renal actions occurred with increases in renal generation of cGMP. The current studies extend previous investigations and report for the first time that BNP decreases proximal tubular reabsorption, as has been reported for ANP (2) . Indeed, the marked natriuretic action of BNP may be mediated by enhancing delivery of sodium to the terminal nephron where additional inhibition of sodium reabsorption results in significant natriuresis despite arterial hypotension. The mechanism of this proximal action remains unclear but like ANP could be mediated by enhanced peritubular physical factors associated with renal vasodilation, augmentation of intrarenal dopaminergic mechanisms, and/or antagonism of intrarenal ANG II (33) .
In striking contrast to normal dogs, in a sodium-retaining state produced by TIVCC, the renal hemodynamic The current study demonstrates that BNP is a potent renal natriuretic and vasoactive peptide that in normal dogs produces renal vasodilatation and natriuresis and reduces arterial pressure in association with the activation of renal and systemic cGMP. In the avid sodiumretaining and edematous state produced by TIVCC, BNP resulted in a greater reduction in arterial pressure in association with activation of systemic cGMP and markedly attenuated renal vasodilatory and natriuretic responses associated with a blunted urinary cGMP response. and natriuretic actions of BNP were absent in association with attenuation of urinary cGMP generation. This demonstrates that in an experimental model of edema with avid sodium retention and activation of the RAAS, BNP renal actions are attenuated. The mechanism of this blunted response may be multifactorial and include ANG II-mediated tubular hyporesponsiveness (24)) aldosterone-mediated enhancement of distal fractional reabsorption of sodium (30) , enhanced local cGMP phosphodiesterase activity altering the intracellular concentrations of cGMP (32) , increased neutral endopeptidase activity limiting the action of BNP (4) , or increased renal nerve activity as previously reported (25). In our study the renal actions of BNP were absent in TIVCC, yet there were increases in urinary cGMP. However, the net renal generation of cGMP, which excludes filtered cGMP from plasma, increased only minimally during the first period and was not significantly different from baseline during the second period. These observations support our hypothesis that renal hyporesponsiveness to BNP in TIVCC is associated with marked attenuation of the renal generation of cGMP. It is unlikely that receptor downregulation contributes to this phenomenon, since BNP like ANP is not elevated in TIVCC. Additionally, the greater decrease in renal perfusion pressure in TIVCC may have been a significant factor in the blunted renal actions of BNP. However, the attenuation of nephrogenous cGMP generation in TIVCC, despite a preservation of the systemic cGMP response, suggests that other intracellular mechanisms contribute to renal hyporesponsiveness to BNP in this sodium-avid state. Because PRA was significantly higher in the TIVCC group it is possible that ANG II may have played an important role in the modulation of the biological actions of BNP.
The current studies confirm previous studies that establish the hypotensive action of BNP (27). The current investigation extends these reports and demonstrates that the mechanism of arterial pressure reduction in both groups is associated with a decrease in cardiac filling pressures and cardiac output consistent with a decrease in preload. Such an action is shared by ANP and is consistent with the reports that BNP and ANP function via binding to a common cGMP-linked receptor (14) . It is also likely that reductions in intravascular volume in association with increased sodium excretion may have contributed to the hypotensive actions of BNP in the control group. In the TIVCC group the arterial hypotensive actions were of a greater magnitude than those in the control group. This occurred despite a lesser decrease in cardiac output and the absence of natriuretic actions. This could be explained by the inability of the TIVCC group, which is characterized by marked peripheral vasoconstriction, to further increase systemic vascular resistance. In addition, the chronic reductions in cardiac preload in the TIVCC group may also result in an enhanced hypotensive response in this setting of intense systemic vasoconstriction and reduced effective plasma volume.
Reports conflict with regard to BNP suppression of PRA in normal humans and animals (1, 17, 36) . Unlike previous reports of a renin-inhibiting action of ANP (2, 5) , in the current study BNP did not decrease plasma renin activity in normal or TIVCC dogs. The lack of suppression of PRA is unclear, since BNP functions via the same receptor as ANP (14) to increase delivery of sodium to the macula densa by decreasing proximal reabsorption of sodium, at least in normal animals. A possible explanation may be that the observed hypotensive response to BNP may have offset the renin-inhibiting actions. In our study, BNP mediated a greater hypotensive response in normal animals than that reported in previous studies and in other studies with comparable doses of ANP. This supports our speculation that stimulated renin release during hypotension may have been suppressed in normal animals. Indeed, studies in which BNP failed to suppress PRA were associated with a significant hypotensive response (36) . While RAP was statistically higher in the TIVCC group at baseline, this difference was minimal and unlike physiological increases with volume expansion or pathophysiological increases with congestive heart failure produced by ventricular pacing or arteriovenous fistula. Therefore, one would predict similar circulating ANP and BNP in TIVCC and controls as was observed. However, previous studies have demonstrated decreases in central venous pressure and decreases in ANP in chronic conscious dogs during caval constriction (6) . This discrepancy in RAP values between TIVCC and controls at baseline is not entirely clear but may be explained by differences in the preconstriction RAP values between the two groups or the effects of pentobarbital anesthesia. In our study circulating ANP and BNP were not significantly different between TIVCC and controls at baseline. Furthermore, total metabolic clearance rate of BNP in the TIVCC group was not significantly different than the control group, suggesting that changes in clearance did not play a role in the observed hyporesponsiveness to BNP in TIVCC. In addition, the modest increases in plasma ANP during BNP administration suggest that in vivo these two peptides may compete for the same clearance receptor as has been demonstrated in vitro (14, 28 ).
Perspectives
The current study provides further insight into the role of BNP in the regulation of renal and cardiovascular homeostasis in the presence and absence of a pathophysiological state of sodium retention and edema similar to states such as heart failure, nephrosis, and cirrhosis. This investigation clearly supports the concept that BNP has potent biological actions in the control of arterial pressure and natriuresis. Thus, when elevated, BNP may complement the actions of ANP. This study also supports the concept that in states of avid sodium retention the renal actions are markedly attenuated and thus the reduced natriuretic action of BNP may contribute to the avid sodium retention associated with these states.
In summary, our studies demonstrate that BNP is a potent renal vasodilator that increases GFR and RBF and enhances sodium excretion by decreasing proximal and distal fractional reabsorption in association with augmentation of RcGMP generation. BNP also produces de- creases in arterial pressure, which are mediated by decreases in cardiac filling pressures and cardiac output in association with activation of systemic cGMP. The results of the present study further establish that the renal hemodynamic and natriuretic actions of BNP are absent in association with a blunted urinary cGMP response in this chronic state of sodium retention and edema. This underscores the role of renal resistance to the natriuretic peptides as a contributing mechanism in the avid sodium retention associated with this cardiorenal disorder.
